MONOCLONAL ANTIBODY INHIBITOR OF FACTOR XIIA
Application
US20260085130A1
Kind: A1
Mar 26, 2026
Assignee
Takeda Pharmaceutical Company Limited
Inventors
Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
Abstract
Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
CPC Classifications
C07K 16/36
A61K 2039/505
C07K 2317/21
C07K 2317/24
C07K 2317/34
C07K 2317/55
C07K 2317/76
C07K 2317/90
C07K 2317/92
C07K 2317/94
Filing Date
2025-08-12
Application No.
19297221